加味癫狂梦醒汤联合西药治疗难治性精神分裂症临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R749.3

基金项目:


Clinical Study on Modified Diankuang Mengxing Decoction Combined with Western Medicine for Treatment-Resistant Schizophrenia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察加味癫狂梦醒汤联合西药治疗难治性精神分裂症(TRS) 的临床疗效。方法:将108例 TRS患者按随机数字表法分为治疗组和对照组各54例。对照组给予阿立哌唑加利培酮治疗,治疗组在对照组 基础上给予加味癫狂梦醒汤治疗。治疗2个月后,比较2组临床疗效及药物不良反应发生率,治疗前后阳性和 阴性症状量表(PANSS) 评分、脑损伤标志物[血清脑源性神经营养因子(BDNF)、神经元特异性烯醇化 酶(NSE)、钙结合蛋白(S100β)] 水平。结果:治疗组总有效率为94.44%,高于对照组81.48%,2组比较, 差异有统计学意义(P<0.05)。治疗前,2组阴性症状、阳性症状、一般精神病理评分及总分比较,差异均无 统计学意义(P>0.05);治疗后,2组上述PANSS量表各维度评分及总分均较治疗前降低(P<0.05),且治疗 组PANSS量表各维度评分及总分均低于对照组(P<0.05)。治疗前,2组血清BDNF、NSE、S100β水平比较, 差异均无统计学意义(P>0.05)。治疗后,2组BDNF水平均较治疗前升高(P<0.05),NSE、S100β水平均较 治疗前降低(P<0.05);且治疗组BDNF 水平高于对照组(P<0.05),NSE、S100β 水平低于对照组(P< 0.05)。治疗组不良反应发生率为7.40%,低于对照组22.22%,2组比较,差异有统计学意义(P<0.05)。结 论:针对TRS患者给予加味癫狂梦醒汤联合西药治疗可提高临床疗效,减轻患者临床症状,调节脑损伤标志物 表达水平,减少药物不良反应。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Modified Diankuang Mengxing Decoction combined with western medicine on patients with treatment-resistant schizophrenia (TRS). Methods: A total of 108 cases of patients with TRS were divided into the treatment group and the control group according to the random number table method,with 54 cases in each group. The control group was treated with Aripiprazole and Risperidone, and the treatment group was additionally treated with Modified Diankuang Mengxing Decoction based on the treatment of the control group. After two months of treatment, Positive and Negative Symptom Scale (PANSS) scores, brain injury markers [serum brainderived neurotrophic factor (BDNF), neuron-specific enolase (NSE), calcium-binding protein (S100β)] levels before and after treatment as well as clinical effects and incidence of adverse drug reactions were compared between the two groups. Results:The total effective rate was 94.44% in the treatment group, higher than that of 81.48% in the control group, the difference being significant (P<0.05). Before treatment, there was no significant difference being found in the comparison of negative symptoms, positive symptoms,general psychopathological scores and total scores between the two groups (P>0.05). After treatment,the scores of all dimensions of PANSS scale and the total scores in the two groups were decreased when compared with those before treatment (P<0.05),and the scores in the treatment group were lower than those in the control group (P<0.05). Before treatment,there was no significant difference in the comparison of the levels of BDNF,NSE and S100β in serum between the two groups (P>0.05). After treatment, the levels of BDNF in the two groups were increased when compared with those before treatment (P<0.05),and the levels of NSE and S100β were decreased when compared with those before treatment (P<0.05);BDNF level in the treatment group was higher than that in the control group (P<0.05), and the levels of NSE and S100β in the treatment group were lower than those in the control group (P< 0.05). The incidence of adverse reactions was 7.40% in the treatment group,lower than that of 22.22% in the control group, the difference being significant (P<0.05). Conclusion: Modified Diankuang Mengxing Decoction combined with western medicine for TRS patients can improve the clinical effect, alleviate clinical symptoms, regulate the expression levels of brain injury markers, and reduce adverse drug reactions.

    参考文献
    相似文献
    引证文献
引用本文

贾文馨,曾欣,袁红卫.加味癫狂梦醒汤联合西药治疗难治性精神分裂症临床研究[J].新中医,2024,56(12):21-25

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-06-28
  • 出版日期:
文章二维码